IN THIS ISSUE

Analysts are predicting a surge of M&A activity in the biotech space, with large pharma firms looking to pad their pipelines with new acquisitions and US tax reform freeing up cash flow. We look at how the biotech M&A landscape is shaping up over the course of 2018.

We also find out why a potential capacity crunch may be on the way for the burgeoning cell and gene therapy market, examine new research that has found that some non-antibiotic drugs affect the growth of gut bacteria, and track the history of drug development for mumps following a recent resurgence of the disease in the US.

Finally, we profile the Swiss pharmaceutical industry, consider whether the UK’s drug approval process is in need of an overhaul, find out how digital technology could unlock billions in savings for pharma companies, and take a closer look at CRISPR, the revolutionary gene-editing tool that can be used to quickly identify drug targets.

Katie Woodward, editor

Go to article: Home | Invest in TechGo to article: In this issueGo to article: Gerteis Company InsightGo to article: GerteisGo to article: ContentsGo to article: DJAGo to article: NewsGo to article: MedelpharmGo to article: Biotech M&A: will the 2018 surge last?Go to article: NSFGo to article: Can the gene and cell therapy revolution scale up?Go to article: Haselmeier GmbH Company InsightGo to article: Haselmeier GmbH Go to article: Gut instinct: how common drugs affect the microbiomeGo to article: HOF Sonderanlagenbau Company InsightGo to article: HOF SonderanlagenbauGo to article: Tracing the story of mumps: a timelineGo to article: Molnar Company InsightGo to article: MolnarGo to article: Inside Swiss pharma: the ideal environment for successGo to article: Is the UK’s drug evaluation system in need of an overhaul?Go to article: Scandinavian Health Ltd. Company InsightGo to article: Scandinavian Health Ltd.Go to article: MoehsGo to article: Could digital tech unlock billions in savings for pharma companies?Go to article: EcocoolGo to article: CRISPR: a seismic shift in gene editingGo to article: Mestra AG (Endress + Hauser)Go to article: EventsGo to article: Pfanstiehl Inc Company InsightGo to article: Pfanstiehl Inc.Go to article: Next issueGo to article: Niconex Medical LtdGo to article: Alpex Pharma SAGo to article: Pall Biotech Company InsightGo to article: Pall BiotechGo to article: AtoZ-CRO GmbHGo to article: WIKA - Disaster preventionGo to article: Bea TechnologiesGo to article: BaxterGo to article: SuezGo to article: Raland Compliance Partners